Caplyta Reduced Bipolar Mania Symptoms in Study
A new study found the treatment significantly lowered mania symptoms in adults compared to a placebo over three weeks.
Updated on Sept. 28, 2026 in Mental Health
Live Poll
If a new psychiatric medication were available for your condition, would you want to try it?
Johnson & Johnson reported that the drug Caplyta met its primary endpoint in a pivotal Phase III trial for bipolar mania. The study of 354 adults showed measurable improvements in mania symptoms starting as early as three days into the treatment.
Why it matters
This development represents a potential move by Johnson & Johnson to expand the therapeutic use of Caplyta beyond its current approval for bipolar-related depressive episodes. For patients and clinicians, these findings suggest a possible new option for managing the manic phase of bipolar disorder.
In a three-week Phase III randomized trial of 354 adults with bipolar I manic episodes, participants treated with Caplyta showed a 4.8-point greater reduction in Young Mania Rating Scale (YMRS) scores compared to those on a placebo. The primary endpoint reached a p-value of less than 0.0001.
The players
Johnson & Johnson
A global healthcare conglomerate that focuses on pharmaceutical research and medical devices.
Intra-Cellular Therapies
A biopharmaceutical company known for developing Caplyta and acquired by Johnson & Johnson.
FirstWord Pharma
A pharmaceutical news and intelligence provider currently polling clinicians on trial results.
The details
Researchers assessed symptom changes using the Young Mania Rating Scale, a standard tool for measuring the severity of manic episodes. The drug demonstrated an effect size of -0.69 during the trial period. While these preliminary findings highlight the treatment's performance in Study 451, Johnson & Johnson plans to conduct a second pivotal trial to further validate its efficacy for this indication.
Timeline
Caplyta received initial US regulatory approval in 2021.
Johnson & Johnson acquired the drug developer in 2025.
Study 451 results were announced on September 21, 2026.
The clinical trial study period lasted three weeks.
Health Landscape
This study marks a significant progression in the clinical development program for Caplyta, which is currently limited to treating bipolar depression. It reflects a broader trend of repurposing established psychiatric agents to cover the full spectrum of bipolar disorder symptoms.
These findings are strictly preliminary and do not change current treatment standards for bipolar mania. Patients should discuss any questions regarding their ongoing management or potential new therapeutic options with their psychiatrist.
The takeaway
While these trial results indicate the drug may help reduce mania symptoms, patients should remain on their currently prescribed treatment plans. Monitor for updates on the second pivotal trial, as these results are essential before the therapy can be considered for a new clinical indication.
Further reading
For more information on how clinicians evaluate new research in psychiatric care, visit Mental Health.
Live Poll
If a new psychiatric medication were available for your condition, would you want to try it?
